Thread by @allseeingFlys

For those who missed the #Novacyt AGM here are some highlights 😊...

2021 Guidance

#Novacyt Small bolt on M&A can be financed from cash

Little reminder IT-IS purchase cost just £10m

Listing plans (AIM, EuroNext, NASDAQ)

"As of today we have no plans to change our listings"

#Novacyt

#Novacyt Midcap plans (£1b >£2b)

Currently working on USA expansion plans, #Novacyt will update market in near future

🇺🇲 Is largest global diagnostics market

37% AIM v 63% EuroNext #Novacyt

#Novacyt have so far do donated 200,000 Genesig tests of 1m to #UNICEF which have not come from excess inventory

Largest #Novacyt growth potential, Point of Care/Near Patient testing 🔬

(q16/q32's/ProMATE)

#Novacyt outlook for COVID testing in the coming years

#Novacyt auditor treatment of DHSC accounting

#Novacyt mainland market strategy will focus on Direct sales

#Novacyt CEO Graham Mullis retirement message as he hands over the keys to David Almond

Congratulations to Graham for years of hard work & vision enabling @NovacytGroup to respond to the pandemic, achieve profitability & setting the company on the path to mid cap status 💫🌟💫

#Novacyt Chairman of the Board James Wakefield thanks Graham for his past endevors & welcomes new CEO David Almond to the business, highlighting his can-do attitude, leadership, commercial experience & recent success with prior companies dual listing on NASDAQ